A-kinase anchoring protein 17A (AKAP17A)

A-kinase anchoring protein 17A (AKAP17A) is a nuclear protein that functions as both a scaffolding protein for protein kinase A and as a splicing factor involved in the regulation of alternative and constitutive splice site selection during pre-mRNA processing[1][4][5][7]. It binds RNA and localizes to nuclear compartments involved in mRNA splicing. AKAP17A is encoded in the pseudoautosomal region of both the X and Y chromosomes and is implicated in pathways that regulate gene expression, protein synthesis, and neural and developmental phenotypes. AKAP17A expression changes are linked to aging phenotypes and may contribute to cognitive decline and reduced physical performance. Its altered dosage is noted in sex chromosome aneuploidy such as Turner and Klinefelter syndromes, suggesting a role in gene dosage sensitivity and developmental regulation[1][4]. There are currently no known drugs that directly target AKAP17A, nor is it a recognized therapeutic target in established pharmacology.

Other names

CCDC133CXYorf3DXYS155EPRKA17AXE7XE7Y721PSFRS17AAKAP-17ASplicing factor arginine/serine-rich 17AProtein XE7Protein kinase A-anchoring protein 17Apseudoautosomal gene XE7B-lymphocyte antigenB-lymphocyte surface antigenMGC39904